Editorial Commentary

Pembrolizumab monotherapy in the first-line treatment of EGFR/ALK wildtype, PD-L1 tumor proportion score (TPS) 1–49%, advanced non-small cell lung cancer (NSCLC): con: “It takes two to tango”